NitroMed, Inc. (NASDAQ: NTMD) today reported financial results for the fourth quarter and the year ended December 31, 2008. Total revenues for the three months ended December...
NitroMed, Inc. (NASDAQ: NTMD) said today that on Friday, January 9, 2009, NitroMed received a letter from Deerfield Management increasing Deerfield?s unsolicited proposal to...
NitroMed, Inc. (NASDAQ: NTMD) said today that Deerfield Management has responded to NitroMed?s communication regarding the company?s willingness to discuss Deerfield?s prior...
NitroMed, Inc. (NASDAQ: NTMD) said today that it has received an unsolicited proposal from Deerfield Management to acquire the company for $0.50 per share in cash. Deerfield...
NitroMed, Inc. (NASDAQ: NTMD) and Archemix Corp., a privately-held biopharmaceutical company working to develop aptamer-based therapeutics, announced today that they have...
NitroMed, Inc. (NASDAQ:NTMD) today announced that JHP Pharmaceuticals, LLC, a privately held specialty pharmaceutical company, has agreed to acquire substantially all of the...
NitroMed, Inc. (NASDAQ: NTMD) reported that on September 16, 2008 it received a letter from The NASDAQ Stock Market?s Listing Qualifications Department providing notification...
NitroMed, Inc. (NASDAQ: NTMD) today reported financial results for its second fiscal quarter and year to date ended June 30, 2008. NitroMed is the maker of BiDil? (isosorbide...
NitroMed, Inc. (NASDAQ: NTMD), announced today that on Tuesday August 5, 2008 it will release financial results for the Company?s second fiscal quarter ended June 30, 2008...
NitroMed, Inc. (NASDAQ: NTMD) today reported financial results for the fiscal quarter ended March 31, 2008. NitroMed is the maker of BiDil? (isosorbide dinitrate/hydralazine...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales